Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)
Others
Ratios

Benitec Biopharma (BNTC) Non Operating Investment Income (2019 - 2023)

Benitec Biopharma's Non Operating Investment Income history spans 5 years, with the latest figure at -$1000.0 for Q4 2023.

  • For Q4 2023, Non Operating Investment Income rose 66.67% year-over-year to -$1000.0; the TTM value through Mar 2025 reached -$1000.0, changed N/A, while the annual FY2024 figure was -$1000.0, 66.67% up from the prior year.
  • Non Operating Investment Income for Q4 2023 was -$1000.0 at Benitec Biopharma, down from $1000.0 in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at $19000.0 in Q2 2021 and bottomed at -$23000.0 in Q4 2021.
  • The 5-year median for Non Operating Investment Income is -$1000.0 (2020), against an average of $0.0.
  • The largest annual shift saw Non Operating Investment Income tumbled 2200.0% in 2021 before it soared 200.0% in 2023.
  • A 5-year view of Non Operating Investment Income shows it stood at -$2000.0 in 2019, then soared by 50.0% to -$1000.0 in 2020, then crashed by 2200.0% to -$23000.0 in 2021, then surged by 86.96% to -$3000.0 in 2022, then surged by 66.67% to -$1000.0 in 2023.
  • Per Business Quant, the three most recent readings for BNTC's Non Operating Investment Income are -$1000.0 (Q4 2023), $1000.0 (Q2 2023), and -$4000.0 (Q1 2023).